Ritlecitinib's 3-Year Alopecia Areata Results in 2026: Nearly 1 in 3 Patients Regrew a Full Head of Hair

Ritlecitinib is a once-daily pill from Pfizer, approved by the FDA in 2023 for severe alopecia areata in adults and adolescents 12 and older. The new analysis followed 191 patients who started with at least 50% scalp hair loss and took the 50 mg daily dose across the ALLEGRO phase 2b/3 study and its long-term extension, ALLEGRO-LT.

By month 36, among patients still in the study, 65.1% reached a SALT score of 20 or less — meaning at least 80% of their scalp was covered with hair. About half (52.3%) reached 90% or better coverage, and 31.2% reached a SALT score of 0: complete scalp regrowth. That last number roughly tripled from year one, when it stood at 11%, which suggests regrowth on this medication can keep building well past the first year rather than plateauing.

The benefits weren't limited to the scalp. Among patients who started with significant eyebrow or eyelash loss, roughly 60% saw meaningful regrowth there too by month 36.

Long-term extension studies have a built-in optimism bias: the people still enrolled at year three tend to be the ones who responded well and tolerated the drug. By the data cutoff, 53.4% of participants had discontinued the study for one reason or another.

The researchers addressed this with a more conservative analysis that carries forward the last recorded result for everyone who left. Under that method, 47.1% still had 80%+ scalp coverage at three years, 36.7% had 90%+ coverage, and 22.5% had complete regrowth. The honest takeaway sits between the two sets of numbers: somewhere between half and two-thirds of patients maintained major regrowth, and roughly a quarter to a third regrew everything. For a condition that until a few years ago had no FDA-approved systemic treatment at all, both readings are meaningful.

It's also worth knowing the study was open-label (everyone knew they were on the drug) and sponsored by Pfizer, which employs several of the authors.

Three years is long enough for rarer problems to surface, so the safety picture matters as much as the efficacy one. Nearly all patients (97.4%) reported some adverse event, but most were mild — headaches and common respiratory infections led the list. Serious adverse events occurred in 6.8% of patients. Shingles (herpes zoster) occurred in 5.2%, a known risk with this class of medication. There were no deaths in the 50 mg group, no major cardiovascular events, one pulmonary embolism, and malignancies other than non-melanoma skin cancer in 1.6% of patients.

Ritlecitinib is a JAK-family inhibitor, a class that carries FDA boxed warnings around serious infection, cardiovascular events, blood clots, and cancer based on data from related drugs. That's exactly why this treatment requires screening — for infections like tuberculosis and hepatitis, and a review of your cardiovascular and cancer history — and ongoing monitoring with a licensed provider rather than a do-it-yourself approach.

This is the most practical question the new data raises, because the right treatment depends entirely on the diagnosis.

Alopecia areata is an autoimmune disease: your immune system attacks hair follicles, often causing smooth, round bald patches that can appear suddenly, sometimes progressing to total scalp or body hair loss. That's what ritlecitinib treats, by calming the immune attack.

Androgenetic alopecia — male- or female-pattern hair loss — is far more common and behaves differently: gradual thinning at the hairline, crown, or part line, driven largely by hormones and genetics rather than immune attack. JAK inhibitors are not the tool for that. Pattern hair loss responds to a different, well-established toolkit: finasteride, dutasteride, and minoxidil, which work by blocking DHT or stimulating follicle activity. Those medications have their own side-effect profiles worth discussing with a provider — minoxidil can cause scalp irritation and early shedding, and finasteride can affect libido in a small percentage of men — but they're backed by decades of data.

If you're not sure which type you have — patchy loss versus gradual thinning — that distinction is the first thing a provider will sort out, and it changes everything about what comes next.

For severe alopecia areata, the message from this data is that durable, even complete, regrowth is a realistic goal for a meaningful share of patients, and that results can keep improving into year two and three. Ritlecitinib is one of a small group of FDA-approved JAK inhibitors for the condition, and choosing among them — or deciding whether a specialist referral makes sense — is a conversation for a dermatologist or licensed clinician who can weigh your disease severity, health history, and insurance coverage.

For the much larger group of people with pattern hair loss, the news is a useful reminder that hair loss treatment has become genuinely effective — but only when the treatment matches the diagnosis. No medication regrows hair for everyone, and anyone promising guaranteed results should be treated with skepticism.

If you're dealing with thinning hair or a receding hairline and want to know your options, JoeyMed's licensed providers can evaluate your hair loss online and, when appropriate, prescribe evidence-based treatments like finasteride, dutasteride, and minoxidil — shipped discreetly to your door. Visit JoeyMed Hair Growth to complete a quick online visit, or explore our wellness services for a broader look at preventive health. A licensed provider will review your history and help you decide whether treatment makes sense for you.